Homepage
Medication Guide
How to Use Anagrelide (Agrylin)
Anagrelide (Agrylin) is a selective thrombocytopenic agent primarily used to treat thrombocythemia secondary to myeloproliferative neoplasms. It reduces the risk of thrombosis and improves related sym...
507
Monday, October 13th, 2025, 14:33
What Are the Side Effects of Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted MET kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. As a...
505
Monday, October 13th, 2025, 14:30
How Effective is Capmatinib (Tabrecta) in Treatment?
Capmatinib (Tabrecta) is a targeted therapeutic agent that has demonstrated favorable efficacy in the treatment of specific types of non-small cell lung cancer (NSCLC) in recent years. As a kinase inh...
508
Monday, October 13th, 2025, 14:14
Precautions for Capmatinib (Tabrecta) Administration
Capmatinib (Tabrecta) is a kinase inhibitor targeting metastatic non-small cell lung cancer (NSCLC) with METex14 skipping mutation. Its efficacy has been verified in clinical trials; however, during m...
507
Monday, October 13th, 2025, 14:10
Precautions for Capmatinib (Tabrecta) Administration
Capmatinib (Tabrecta) is a kinase inhibitor targeting metastatic non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping mutations. Its efficacy has been validated in clinical trials; h...
509
Saturday, October 11th, 2025, 17:16
Indication of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a small-molecule inhibitor targeting the MET kinase, developed by Novartis and granted accelerated approval by the U.S. FDA in 2020. As a precision therapy, it has demonstrate...
510
Saturday, October 11th, 2025, 17:13
How to Administer Cemiplimab
Cemiplimab is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not ca...
511
Saturday, October 11th, 2025, 16:25
Precautions for Cemiplimab Administration
Cemiplimab is a PD-1 inhibitor indicated for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or radia...
504
Saturday, October 11th, 2025, 16:03
What Are the Side Effects of Cemiplimab?
Cemiplimab is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not ca...
508
Saturday, October 11th, 2025, 15:22
How to Purchase Zongertinib
Zongertinib is a targeted therapeutic agent for non-small cell lung cancer (NSCLC) harboring activating mutations in the tyrosine kinase domain of HER2 (ERBB2). Due to its specificity and potential ef...
505
Saturday, October 11th, 2025, 15:03
94 / 207
2069 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved